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Abstract
Background: Bone metastasis (BM) is the most common site of disease in metastatic breast cancer (MBC) patients.
BM impacts health-related quality of life (HRQoL). We tested prospectively the psychometric properties of the Bone
Metastasis Quality of Life (BOMET-QoL-10) measure on MBC patients with BM.
Methods: Patients completed the BOMET-QoL-10 questionnaire, the Visual Analogue Scale (VAS) for pain, and a
self-perceived health status item at baseline and at follow-up visits. We performed psychometric tests and
calculated the effect size of specific BM treatment on patients´ HRQoL.
Results: Almost 70% of the 172 patients reported symptoms, 23.3% experienced irruptive pain, and over half were
receiving chemotherapy. BOMET-QoL-10 proved to be a quick assessment tool performing well in readability and
completion time (about 10 min) with 0–1.2% of missing/invalid data. Although BOMET-QoL-10 scores remained
fairly stable during study visits, differences were observed for patient subgroups (e.g., with or without skeletal-
related events or adverse effects). Scores were significantly correlated with physician-reported patient status,
patient-reported pain, symptoms, and perceived health status. BOMET-QoL-10 scores also varied prospectively
according to changes in pain intensity.
Conclusions: BOMET-QoL-10 performed well as a brief, easy-to-administer, useful, and sensitive HRQoL measure for
potential use for clinical practice with MBC patients.
Trial registration: NCT03847220. Retrospectively registered on clinicaltrials.gov (February the 20th 2019).
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Introduction
Breast cancer represents 25% of all cancer cases worldwide
[1]. Between 6% and 10% of them will present as meta-
static breast cancer (MBC) at diagnosis [2]. Between 30%
and 40% of those receiving adjuvant or neoadjuvant
chemotherapy for early-stage disease will eventually de-
velop MBC [3, 4]. Thanks to the incorporation of new
therapeutic agents to cancer treatment and a better dis-
ease management, the median survival has increased in
patients with advanced disease over the years. Patients live
longer and health-related quality of life (HRQoL) becomes
a great outcome of interest in MBC-related research [3, 4].
Bone metastasis (BM), the most common site of dis-
ease in MBC patients [5], greatly impacts HRQoL due to
its high morbidity [6–9]. In addition, treatment-related
toxicities are generally under-reported by physicians
when compared to patients´ reports [10]. Surprisingly,
how and to what extent MBC symptoms, MBC-related
treatments, or palliative care may affect patients´
HRQoL remains understudied [11–14].
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Better understanding of the disease’s overall impact on
HRQoL requires questionnaires designed to assess pa-
tients’ perception of their pain and other potentially life-
limiting symptoms. The questionnaire designed by the
European Organization for Research and Treatment of
Cancer (EORTC), QLQ-C30, and the functional assess-
ment of cancer therapy (FACT-G) assess general cancer-
related HRQoL issues. The corresponding breast cancer
modules focus on image and sexual life issues, lymph-
edema of the arm, and surgery incision pain, i.e., chal-
lenges found in both metastatic and non-metastatic
patients. However, 50–70% of patients with BM present
with bone pain and related threats to HRQoL [15]. The
Quality of Life Questionnaire-Bone Metastasis-22 (QLQ-
BM22), a 22-item submodule of QLQ-C30 [15], and
Bone Metastasis Quality of Life (BOMET-QoL), a 25-
item questionnaire [16], were designed to fill this gap by
targeting cancer patients with BM.
BOMET-QoL was later reduced to 10 items (BOMET-
QoL-10) and validated using a similar population of pa-
tients with BM. In that validation study, factorial ana-
lyses identified a single dimension which accounted for
45.8% of explained variance. The disease’s impact on
HRQoL did not vary significantly across clinical variables
such as number and location of bone metastases and
time since diagnosis. However, it did vary significantly
by presence, number, and duration of irruptive pain cri-
ses, pain management index (PMI), and Eastern Co-
operative Oncology Group Performance Status (ECOG
PS) [17]. Reported impact on HRQoL was lower with
fewer irruptive pain crises when pain control was satis-
factory (PMI = 0) or when ECOG PS score was between
0 and 1 [18].
In most cases, BOMET-QoL-10 questionnaire scores
correlated statistically significantly, and at least moder-
ately, with EORTC QLQ-30 and BOMET-QoL dimen-
sions, confirming convergent validity. Also, BOMET-
QoL-10 scores experienced a statistically significant in-
crease (i.e., improved HRQoL) throughout the study
[18]. The effect size between the baseline visit and the 6-
month follow-up was 0.841. BOMET-QoL-10 showed
the capacity to detect changes in perceived health status
(between 3 and 6months), pain perception, and ECOG
PS score throughout the study. This indicates that
BOMET-QoL-10 is able to detect changes in relevant
conditions. The instrument also exhibits good internal
consistency (Cronbach’s α =0.93) and good test-retest
reliability (Intraclass Correlation Coefficient = 0.94). The
result is a useful 10-item measure of HRQoL easy-to-use
in both clinical trial interventions and in regular clinical
practice [18]. Previously, Adrover and colleagues (2005)
were unable to evaluate the psychometric properties and
clinical utility for specific types of cancer, such as MBC,
due to sample size limitations [16].
MBC patients with BM have disease-specific complica-
tions with particular impacts on HRQoL. Thus, the main
objective of the present study was to evaluate the aplic-
ability of BOMET-QoL-10 in this patient population, re-
gardless of treatment received. Secondary objectives
included: 1) Evaluating the differences on BOMET-QoL-
10 scoring when patients have skeletal-related events
(SREs) and BM symptoms; 2) Exploring the association
between BOMET-QoL-10 scores and other measures of
self-perceived health status and pain such as ECOG PS
and Visual Analog Scale (VAS); and 3) Assessing
whether the magnitude of the effect of BM treatment on
patients´ HRQoL reaches clinical significance.
Materials and methods
This was a prospective, observational, multicenter study
of MBC patients who received systemic therapy accord-
ing to local guidelines. MBC patients were eligible for in-
clusion with age above 18 and diagnosed with BM,
ability to understand and complete the questionnaires,
estimated life expectancy of at least 8 months, and ab-
sence of co-morbidities.
Study visits were pre-specifed in the protocol as a first
baseline visit and 6 follow up visits at 4, 8, 12, 16, 20 and
24months after baseline visit.
Figure 1 shows the study timeline. The following data
were collected: 1) Basic socio-demographic data: age at
study entry and family support; 2) Clinical data: date of
diagnosis, stage of disease at diagnosis, site(s) and date
of diagnosis of BM and visceral metastases at baseline;
SREs, MBC-related symptoms, type of irruptive pain cri-
ses if any, treatments for breast cancer and for BM,
chronic osteoarticular comorbidities and their treatment,
other chronic diseases, and ECOG PS score were col-
lected by the physician at baseline and throughout the
study; 3) Safety measures: clinically-relevant adverse
events (AE) and their grades and blood tests (especially
creatinine, calcium, and albumin) were collected during
each follow-up visit.
To assess HRQoL and perceived health data partici-
pants completed the BOMET-QoL-10 questionnaire
(Additional file 1) and the VAS for pain at study visits in
the hospital. The questionnaire was administered to the
patients on paper by trained study site personnel. In the
BOMET-QoL-10 patients were asked to respond to
questions based on a 5-point Likert scale ranging from
“never” (4) to “always” (0). The VAS for pain was a con-
tinuous 10 cm line where the patients have to mark the
pain they were experiencing at that moment (left side of
the line was no pain and the other end was unbearable
pain). Perception of general health status was collected
at baseline and reports of changes in perceived health
status (compared to that at baseline) were collected at
follow-up visits. General health status was based on both
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patient’s and health professional’s responses ranging
from “very good” to “very bad” on a 7-point Likert scale.
Statistical analysis
Initially, we calculated the need to recruit 241 patients
based on the following assumptions: a standard deviation
(SD) of 23 points for BOMET-QoL-10 scores (same as
BOMET-QoL), a 20% patient drop-out rate, an estima-
tion of HRQoL with a precision of ±3.25, and having at
least 80% power to detect a difference ≥ 0.20 SD between
BOMET-QoL-10 scores at baseline and at last follow-up
(visit 7) with a 0.05 level of significance. However, due
to recruitment limitations, we recalculated the target re-
cruitment to 174 by slightly lowering our precision in es-
timating QoL to a ± 3.75 instead, while keeping the
other parameters the same.
Categorical variables were described using frequencies
and their differences were tested using Chi-square (χ2)
or Fisher exact tests. Associations between ordinal vari-
ables were described using Kendall’s Tau. We used
means, standard deviations, medians, and ranges (mini-
mum and maximum) to describe continuous variables.
Depending on variables’ distributions either Student t-
tests or Mann–Whitney U-tests were used for compari-
sons. Likewise, we used Pearson r coefficients or
Spearman’s rank correlation coefficients (ρ) to assess as-
sociations between variables of interest. Relationships
between BOMET-QoL-10 scores and ECOG PS scores,
perceived health status, and presence of SREs and AEs
were analyzed.
To assess the BOMET-QoL-10 scores we calculated
the mean score value in every visit for every item and a
global standardized mean score of the whole question-
naire. This value was performed taking into account
those questionnaires completely fulfilled (10 questions).
The higher the BOMET-QoL-10, the higher quality of
life (HRQoL).
To assess the clinical usefulness of our results we cal-
culated the effect size of the questionnaire’s scores for
patients receiving any specific medical intervention for
BM, at any visit(s) during the study, versus patients who
did not. The minimum effect size (d) for the difference
between groups to be considered a clinically significant
improvement in HRQoL was set at d ≥ 0.20. The effect
size was calculated using the standardized mean differ-
ence, defined in this case as the ratio of the difference in
mean scores between baseline and last follow-up and the
standard deviation of scores at baseline.
To evaluate the correlation between the reduction in
pain (according to pain VAS) and the HRQoL on the
BOMET-QoL questionnaire, we compared the difference
of mean values of those parameters between baseline
and last follow-up visit.. We categorized this as: “Gets
worse” if the difference was negative, “Stays the same” if
the difference was zero and “Improves” if the difference
was positive.
Finally, to evaluate the evolution of BOMET-QoL-10
scores, when explicitly mentioned, certain analyses only
included those questionnaires with no missing data. All
tests were two-tailed with an α = 0.05. Analyses were
conducted using SPSS version 17.0 (SPSS Inc., Chicago
IL, 2008).
Results
From October 2007 to May 2010, 174 patients were re-
cruited at 15 GEICAM hospitals distributed throughout
Spain. One hundred seventy-two were eligible and en-
rolled in the study. Only 83 of them completed the last
follow-up visit at 24 months. Missing data for specific
questions or instruments varied across assessments, as
reflected in in Tables 1 and 2.
Patients’ median age was 59 years (range: 30–89) and
only 14% lived alone. The median time between breast
cancer diagnosis and study enrollment was 4.4 years
(Range: 0–36.8). Over half of the patients (52.7%) were
stage IV at diagnosis. The most common BM sites were
the spine (76.2%), pelvis (53.5%), and ribs (45.3%). In
addition, visceral metastases were present in 40.7% of
Fig. 1 Study timeline
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patients. SREs were reported in 18.6% of patients, the
most common one being pathologic fractures (25.0%).
Almost 70% of patients presented symptoms, mostly
lower back pain (37.0%) and weakness (32.8%). Further,
23.3% of patients presented irruptive pain, of whom,
72.5% reported the pain to be incidental and clearly
linked to oncological and neuropathic pain. Over 50% of
patients presented chronic conditions, 19.2% were
osteoarticular and 34.3% were non-osteoarticular
comorbidities. (Table 1). More than half of the patients
had a baseline ECOG PS score of 1 (51.2%) and 37.3%
had a score of 0.
At baseline 54.7% of patients were receiving chemo-
therapy, 58,1% were on hormone therapy, and 12.2% re-
ceived other treatments including bisphosphonates,
palliative radiotherapy for bone metastasis or orthopedic
surgery (Additional file 2). Patients could be receiving
more than one treatment concurrently and they contin-
ued receiving treatments during follow-up visits. Overall,
at each follow-up the proportion of patients receiving
any one treatment grew smaller, except hormone
therapy, but still with a marked downward trend. For
instance, at the 24-month follow up, only 16.9% were
receiving chemotherapy, 1.2% radiotherapy, 20.5%
endocrine therapy, and 4.8% other treatments (anal-
gesic, anti-inflamatory therapy and some rehabilita-
tion). Patients were also treated for BM with
bisphosphonates (79.1%) and pain relievers (37.8%) As
with MBC treatment, the proportion of patients re-
ceiving treatment for BM tended to decrease at each
follow-up (Additional file 3).
The vast majority of patients (80%) completed the
BOMET-QoL-10 in less than 10 min in all visits, with a
high completion rate. The small proportion of un-
answered items throughout the entire follow-up ranged
between 0% and 1.2%. Based on fully-completed ques-
tionnaires, we calculated the global average score for
each visit from baseline (n = 172) to the 24-month
follow-up (n = 83). There was no significant trend in
BOMET-QoL-10 scores over the 7 visits. In fact, base-
line and last follow-up global average scores (25.6 [SD
8.0] and 25.9 [SD 8.2], respectively) were were not statis-
tically significant different (Additional file 4). Similarly,
there were no a regular behavior for each of the 10 items
of the questionnaire across visits and there were no
items more likely to be skipped than others. However,
there were two items with a tendency to receive lower
scores, reflecting worse HRQoL, than the rest: “I feel
tired” and “I have pain in some areas of my body such as
my back, legs, hips, … that affect my life” and two items
that tended to get higher scores reflecting better
HRQoL, than other items: “I avoid family activities” and
“I have an intense pain that doesn’t leave me alone.”
Further, as expected, BOMET-QoL-10 lower scores
were negatively correlated with the number of BM-
related symptoms (ρ = − 0.410, p < 0.001) (Add-
itional file 5) as well as with VAS pain global standard-
ized mean scores (ρ = − 0.542, p < 0.01). These patterns
of correlations held true for the scores reported in every
visit (Table 2). In addition, 32 patients whose pain im-
proved between baseline and last follow-up visit (visit 1
vs 7, Table 2) reported significantly higher BOMET-
QoL-10 average scores compared to those whose pain
Table 1 Baseline patient characteristics (n = 172)
Characteristics Value
Age (years), median (Range) 58 (30–89)




Upper limbs 24 (14.0)
Lower limbs 48 (27.9)
Skull 37 (21.5)
Other 48 (27.9)
Visceral metastasis, n (%) 70 (40.7)
Patients with skeletal related events, n (%) 32 (18.6)
Pathologic fractures 8 (25.0)
Hypercalcemia 1 (3.1)
Medullar compression 1 (3.1)
Need for surgery 8 (25.0)
Need for radiation therapy 21 (65.6)
Patients with symptoms, n (%) 119 (69.2)
Lower back pain 44 (37.0)
Hip pain 32 (26.9)
Rib pain 27 (22.7)
Asthenia 39 (32.8)
Arthromyalgia 7 (5.9)
Other bone pain 8 (6.7)
Other 23 (19.3)




Patients with non-osteoarticular comorbidities, n (%) 59 (34.3)
Chronic Obstuctive pulmonary disease (COPD) 1 (7)
Dislipemia 18 (30,5)
Cardiovascular disease 7 (11.9)
Arterial hypertension 35 (59.3)
Diabetes mellitus 11 (18.6)
Other 25 (42.4)
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remained at the same level or worsened (29.4, SD = 7.7
vs.24.0, SD = 7.8; p = 0.003).
Most patients (85.5%) reported ECOG PS scores be-
tween 0 and 1. We compared BOMET-QoL-10 scores
for each visit between two groups formed by patients
with ECOG PS scores 0–1 versus those with ECOG PS
scores > 1, to assess the differences in QoL within these
groups. The former reported significantly higher
BOMET-QoL-10 scores (range: 26.5 to 28.0) than the
latter (range: 17.3 to 22.9). Differences between patients
with ECOG PS 0–1 and > 1 were statistically significant
overall and for every visit, except in visit 3 (Table 3).
The BOMET-QoL-10 and perceived health status scores
were also moderately inversely correlated for all 7 visits
(range: − 0.6 to − 0.3; p < 0.001 for all).
We also evaluated the values of BOMET-QoL-10
scores for those patients (up to 42 patients between
visits 4 and 5) reporting their perceived health status be-
tween visits remaining “more or less the same.” As ex-
pected, their corresponding BOMET-QoL-10 scores did
not vary between consecutive visits either. There were
26 highly stable patients who reported the same per-
ceived health status from baseline all throughout the last
follow-up. As expected, BOMET-QoL-10 global mean
for these highly stable patients was unchanged between
baseline and visit 7 (26.4, SD = 8.8 and 26.4, SD = 7.0, re-
spectively) (p = 0.956). Thus, BOMET-QoL-10 scores for
highly stable patients were consistently stable through-
out the study.
In addition we compare the BOMET-QoL-10 scores
between patients with SREs and/or AEs and patients
with neither, as well as the questionnaire’s power of dis-
crimination between these two groups, we compared
their average scores for each visit (Fig. 2). Results show
that the average score for each group remained fairly
stable (range: 21.8 to 24.0 for the former and range: 26.1
to 28.5 for the latter). The mean differences between the
two groups were in the expected direction and statisti-
cally significant in 4 of the 7 visits while approaching
significance in the other 3 visits. Further, we tested the
difference between the overall average score (all 7 visits)
between patients ever reporting SREs and/or AEs at any
of the visits during the 2 year-follow up (n = 111; mean =
24.1, SD = 7.2) and that for patients reporting neither
SREs nor AEs at any of the visits during the same period
(n = 61; mean = 26.8, SD = 7.4). The average score for the
Table 2 Relationship between HRQoL according to BOMET-QoL-10 and pain VAS
Bomet-QoL-10 HRQoL questionnaire
Visits Pain VAS Gets worse No change Improves Correlation (Kendall’s Tau-b) p-value
1 vs 2
n = 133
Gets worse 33 5 19 0.232 0.003
No change 7 4 5
Improves 19 7 34
2 vs 3
n = 106
Gets worse 37 6 13 0.466 < 0.0001
No change 3 1 2
Improves 8 4 32
3 vs 4
n = 97
Gets worse 23 6 9 0.271 0.002
No change 5 1 7
Improves 15 5 26
4 vs 5
n = 92
Gets worse 28 6 11 0.348 < 0.0001
No change 5 1 2
Improves 12 0 27
5 vs 6
n = 72
Gets worse 24 0 11 0.373 0.001
No change 1 4 2
Improves 8 2 20
6 vs 7
n = 69
Gets worse 25 3 8 0.432 < 0.0001
No change 1 4 1
Improves 7 2 18
1 vs 7
n = 79
Gets worse 31 0 12 0.464 < 0.0001
No change 1 1 2
Improves 13 1 18
HRQoL Health Related Quality of Life
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first group was significantly lower than that of the sec-
ond group (p ≤ 0.007) (data not shown).
Finally, MBC patients receiving specific treatment
for BM reported a clinically significant improvement in
HRQoL throughout the study compared to those
patients who did not. The magnitude of the treatment’s
effect for BM was calculated as the difference between
the BOMET-QoL-10 mean values at visit 7 in these two
groups divided by a combined standard deviation. The
relative overall study variability yielded an effect size of
0.203 in BOMET-QoL-10 scores, which is greater than
our pre-set value for clinical significance (0.200)
(Table 4)).
Discussion
With increasing rates of survival after a breast cancer
diagnosis a growing number of patients are at risk for
MBC [1, 19]. For MBC patients, whose treatments are
essentially palliative, an accurate and clinically valid as-
sessment of HRQoL is particularly important. Thus, in-
struments should be comprehensive enough to capture
the key aspects of a patients´ quality of life, though still
easy to understand and brief. This could remain as a
feasible tool to be used in clinical practice [20, 21].
Aside from BOMET-QoL, QLQ-BM22, a widely used
tool, is the only other HRQoL instrument designed spe-
cifically for BM patients. QLQ-BM22 is a useful and reli-
able instrument especially when administered in
combination with the QLQ-C30 [22, 23]. Several studies
Table 3 BOMET-QoL-10 scores throughout the study by ECOG
PS
Mean SD p
Visit 1 (n = 166)
ECOG 0–1 26.5 7.6 0.003
ECOG > 1 19.8 9.2
Visit 2 (n = 143)
ECOG 0–1 26.5 7.9 0.002
ECOG > 1 18.0 8.6
Visit 3 (n = 120)
ECOG 0–1 26.7 7.4 0.111
ECOG > 1 22.9 7.2
Visit 4 (n = 115)
ECOG 0–1 27.2 7.6 0.000
ECOG > 1 17.3 7.3
Visit 5 (n = 95)
ECOG 0–1 28.0 7.5 0.004
ECOG > 1 18.9 10.6
Visit 6 (n = 76)
ECOG 0–1 27.8 7.3 0.036
ECOG > 1 19.0 8.9
Visit 7 (N = 76)
ECOG 0–1 27.3 7.6 0.005
ECOG > 1 17.3 8.1
ECOG PS Eastern Cooperative Oncology Group Performance Status
SD Standard Deviation
Fig. 2 BOMET-QoL-10 mean scores for each visit over time reported by patients with AEs and/or SREs versus patients with neither. Higher scores
indicate better Health Related Quality of Life.*Mean scores are statistically different between patient groups (p < 0.05)
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have evaluated and validated the QLQ-BM22 module
with male and female patients of a variety of primary
cancers and BM, and/or residing in a variety of countries
as summarized below. However, despite its satisfactory
psychometric properties, caution is warranted when
comparing certain items by gender or country as they
may function differently [24]. Raman and colleagues
(2016) [23] validated the module based on a sample of
204 men and women diagnosed with one of at least six
different cancers and BM. Patients were assessed at
baseline and at a 42 day-follow-up. Another international
study evaluated the module’s performance based on two
administrations—1 month apart— to 59 patients from 6
different countries [9]. A larger 7-country study adminis-
tered the module twice—1 month apart—to 400 male
and female patients diagnosed with at least 9 different
cancers with BM [25]. Recently, Lin and Pakpour (2016)
[24] performed a psychometric evaluation of QLQ-
BM22 based on a pre-treatment single administration of
a pooled sample of 573 BM patients from 8 countries.
Miki-Rosário and colleagues (2016), [26] validated the
Brazilian Portuguese translation of the QLQ-BM22
based on a sample of 95 men and women with BM de-
rived from 9 different cancers. Reliability, face and con-
tent validity were assessed based on 40 patients over
three administrations of the module. The use of other
tools not designed specifically for BM patients (e.g., Brief
Pain Inventory, the QLQ-C30 alone, the QLQ-C15 PAL,
the Net pain relief concept, and the Spitzer’s QOL
Index) to assess QOL in patients with BM has been
reviewed by McDonald and colleagues [8].
BOMET-QoL-10 has been shown to closely reflect
variations in relevant pain and wellness measures, having
good internal consistency, and being highly reliable
among cancer patients with BM [18, 22]. Our objective
in this study was to evaluate whether the BOMET-QoL-
would be a valuable tool to use for breast cancer patients
with BM. The questionnaire was tested at baseline on a
MBC patient population in which 70% of individuals re-
ported symptoms, close to a quarter experienced irrup-
tive pain, over half presented chronic conditions, and
more than half were receiving chemotherapy. BOMET-
QoL-10 proved to be a quick assessment tool perform-
ing well in terms of readability and completion time
(about 10 min); and presenting very low levels of missing
or invalid data (0–1.2%) throughout all 7 follow-up
visits. Quick completion is important in the context of
clinical practice not only because of the inherent time
limitations but also because it reduces response burden
in patients who may be experiencing chronic pain and/
or who may fatigue easily during assessments. Thus, sin-
gle instruments are preferred over two or more [27].
Whereas succinctness is important, items highly relevant
to the patient’s experience are also key to keeping sub-
ject burden low [21]. Our results convey low administra-
tion burden and high content relevancy. Acceptable
subject burden is a key factor for achieving high comple-
tion and response rates as well as high data quality [28].
BOMET-QoL-10 scores for overall HRQoL remained
stable over time for the sample as a whole. This lack of
variability may reflect the influence of aspects other than
the socio-demographic and clinical factors assessed here.
However, when patients were grouped by disease status
(e.g., with or without SRE and/or AE) BOMET-QoL-10
scores reflected the differences in group wellness one
would expect at each visit and throughout the study
(had SREs and/or AEs at any of the visits vs. not). Fur-
ther, the instrument’s scores were significantly correlated
with physician-reported patient status, patient-reported
pain, symptoms, and perceived health status. Perceived
pain was directly proportional to HRQoL and VAS
scores and BOMET-QoL-10 scores also varied accord-
ingly as patient’s pain improved or worsened. As ex-
pected, the BOMET-QoL-10 and ECOG PS scores were
inversely proportional throughout the study. This sup-
ports previously reported results based onQLQ-C30 and
QLQ-BM22 [23, 25, 29]. We should highlight that in
some of the categories, the effect was the opposite, but
this was most likely due to the low number of patients
in those categories. Overall, these results suggest that
the BOMET-QoL-10 is a reliable and useful, tool to
measure of HRQoL in this patient population.
Finally, we assessed the instrument’s sensitivity to
change by calculating the effect size for patients who
had received BM-specific medical intervention versus
those who had not. We then compared it to an a priori
value we considered to be minimum clinically relevant
effect. The BOMET-QoL-10 effect size was greater than
the pre-set value. Thus, MBC patients receiving specific
treatment for BM reported a clinically relevant improve-
ment in HRQoL throughout the study compared to
MBC patients who did not. This confirms that the in-
strument is sensitive to changes independently of the
statistical significance of other results [16].
The study presents limitations which should be con-
sidered when interpreting our results. First, a majority of
patients (71.5%) were recruited by 5 of the 15 participant
research centers. As palliative care populations tend to
Table 4 Effect size of the global BOMET-QoL-10 mean values at





Mean SD N = 83 % D
No 27.08 7.24 24 28.9% 0.203
Yes 25.41 8.61 59 71.1%
Abbreviations: D Effect size
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be highly heterogeneous, a limited number of recruiting
centers may have resulted in a less diverse sample of
participants than expected. This may have introduced an
unknown bias [30] and reduced the generalizability of
the results. However, it is not uncommon for samples to
be drawn from one or a handful of medical facilities [29,
31]. Second, due to feasibility concerns the study is
based on a non-probability sample which removes the
possibility of estimating sampling variability or to ascer-
tain potential biases. Research centers such as Statistics
Canada, nonetheless, use non-probability sampling for
questionnaire testing [32].
A third limitation is the small number of patients
completing the entire 24-month study. This is the result
of an initial small sample size compounded by a much
higher lost-to-follow-up rate (51.7%) than anticipated
(20%). However, recent adaptation and validation studies
of HRQoL instruments as well as HRQoL assessments of
palliative care patients have been based on small samples
followed for short periods of time ranging from 1 to 6
months [9, 23, 26].
Unfortunately, the lower numbers limited the evalu-
ation of the study’s secondary objectives and actual dif-
ferences may have gone undetected given the low
statistical power of some of our comparisons. For in-
stance, even though BM-associated pain is quite com-
mon and often undertreated in MBC patients [33],
BOMET-QoL-10 failed to statistically differentiate the
HRQoL of patients with AEs and/or SREs versus those
with neither one in 3 of the 7 visits even when they were
substantial in magnitude and clearly of clinical signifi-
cance. These differences, which approached significance,
most likely would have reached significance in a larger
sample. In fact, when we compared patients ever report-
ing SREs and/or AEs during the 2-year study (n = 111)
to those who did not report either during the study (n =
61) their overall average scores were significantly differ-
ent (p < 0.007).
The study also has some important strengths. First,
the longitudinal administration of the same tool to
patients with BM in seven occasions over a 2-year
period represents a solid assessment of the user-
acceptance, respondent burden of the tool, and stabil-
ity of the measurement. As aforementioned, this con-
trasts with other studies which include just one or
two follow-ups over periods of time under 1 year [9,
16, 18, 23, 26], with the exception of Jordhøy and
colleagues who followed 395 patients for 2 years [29].
Second, our main overall outcome, patients´ HRQoL,
was assessed by three methods in addition to
BOMET-QoL-10: the doctor’s perception, the patient’s
perception, and the VAS score. These assessments
were highly associated suggesting that BOMET-QoL-
10 has a high construct validity. Third, certain
dimensions of HRQoL are subjective and may be af-
fected by gender, site of original tumor [16], type of
therapy administered or cultural norms and expecta-
tions in unknown ways. Our results minimize this po-
tential negative interaction by using a fairly
homogenous patient sample (female MBC patients
residing in Spain). In contrast, many of the studies
evaluating or using QLQ-BM22 or BOMET-QoL-10
are based on patients of both genders, diagnosed with
different primary cancers, and/or recruited across
countries with different cultures and languages [9, 16,
18, 23, 26, 29].
Conclusions
The regular surveillance of HRQoL issues in patients
with advanced disease and receiving palliative care
can be used to guide pain management therapy [34]
and other symptoms and choose the best course of
palliative action for patients [26]. The development of
quality easy-to-administer tools such as BOMET-
QoL-10 will facilitate such needed surveillance. Al-
though, not as comprehensive as other assessments,
BOMET-QoL-10’s brevity and relevancy allow the
clinician to accurately and efficiently assess some rele-
vant quality of life aspects in patients with breast can-
cer and BM. In only 10 min and without burdening
symptomatic frail patients, this reliable and useful tool
identifies key quality of life aspects in a regular clin-
ical setting.
This instrument exhibits longitudinal and cross-
validation, construct validity, as well as feasibility and it
is sensible to detect some changes related with the dis-
ease evolution and their treatment. BOMET-QoL-10 is
sensitive to the number of symptoms, pain level, ECOG
PS, presence of SREs and/or AEs, and the effects of BM-
specific treatment.
Further research is needed to test this tool in larger
samples of breast cancer patients with BM as well as in
other homogenous cancer populations with BM, e.g.,
prostate or lung cancer patients with BM. Further steps
would involve translation and cross-cultural adaptation
of the tool to other languages and countries.
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